Volitinib (Savolitinib), SAR125844, tepotinib (EMD1214063), capmatinib (INCB28060), AMG337, Indo5, tivantinib, and PHA665752 are of such selective c-Met inhibitors [156,157,158,159,160], which showed anti-tumor effects in various cancers with high MET expression, including gastric and hepatocellular carcinoma, papillary renal carcinoma, and NSCLC [158, 161]
2 A monogenic type of EDS, previously called tenascin-X (TN-X) deficient EDS, was first reported in 1997
Observed responses in research settings are generally reported as mild and may include: Temporary injection-site irritation Redness or warmth sensations Skin-sensitivity variability Temporary blue-tinted discoloration beneath the administration area Localized irritation depending on dosage range, concentration, administration frequency, protocol duration, and individual sensitivity Research protocols commonly investigate daily administration ranges between: 12mg daily in standard research settings Up to 3mg daily in more advanced experimental protocols GHK-Cu is frequently explored in continuous or maintenance-style research structures and does not always require strict cycling protocols in moderate-dose experimental models
While there is no quick fix for improving health, glutathione comes close